Get all your news in one place.
100's of premium titles.
One app.
Start reading
Medical Daily
Medical Daily
Health
Cole Mercer

Adding Belzutifan or a CTLA-4 Drug Failed to Beat Keytruda Plus Lenvima in 1,688-Patient Kidney Cancer Trial

Adding a third drug to the standard Keytruda and Lenvima combination did not help patients with advanced kidney cancer live longer or keep their cancer in check longer at a planned interim analysis of a large Phase 3 trial. Researchers will present the full results on October 25 at the European Society for Medical Oncology (ESMO) Congress in Madrid.

The LITESPARK-012 trial randomly assigned 1,688 previously untreated patients with advanced clear cell renal cell carcinoma to one of three regimens. More patients on the triple-drug combinations stopped treatment, according to Dana-Farber Cancer Institute.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.